United States Patent 7,795,316: Scope, Claim Boundaries, and Patent Landscape for a Tobramycin/Dexamethasone + Deacetylated Xanthan Gum Topical Ophthalmic Composition
US Drug Patent 7,795,316 claims a specific ophthalmic formulation built around (i) tobramycin plus dexamethasone, (ii) a deacetylated xanthan gum viscosity system, and (iii) controlled ionic environment defined by a sodium chloride equivalent (SCE) ionic concentration window (134 to 150 mM), with viscosity and pH constraints tied to measured rheology. The independent claim is tightly engineered: it requires a combination of drug actives, polymer type and concentration, ionic concentration, pH, and viscosity performance at defined shear and temperature.
The claim set in your excerpt includes composition claims (1-11, 14-19) and method claims (12-13). Claims 14-19 appear to recast the composition with an explicit in vitro/in vivo viscosity ratio limitation and additional narrowing selections.
What is the core invention in Claim 1?
Claim 1 defines a topical ophthalmic composition comprising the following coupled limitations:
A. Actives
- Tobramycin: 0.1 to 0.5 w/v %
- Dexamethasone: 0.03 to 0.1 w/v %
B. Vehicle / rheology modifier
- Aqueous, ophthalmically acceptable vehicle containing deacetylated xanthan gum at 0.3 to 0.9% (w/v)
C. Ionic species requirement (to control polymer-drug interactions)
- One or more ionizable species present in an amount sufficient to limit ionic interactions between tobramycin and deacetylated xanthan gum
- This limitation is functionally anchored to rheology performance:
- in vitro viscosity maintained within 10 to 300 cps
- measured at shear rate 6 sec−1
- at 25°C
D. Ionic concentration window
- The ionizable species must have an SCE (sodium chloride equivalent) ionic concentration of 134 to 150 mM
E. pH
This is not a generic “tobramycin + steroid + thickener” claim. The polymer is specified by identity (deacetylated xanthan gum) and the formulation is constrained by measured viscosity, measurement conditions, pH, and ionic strength expressed as SCE.
How do dependent claims narrow Claim 1?
Which ionizable species are allowed?
- Claim 2: ionizable species selected from inorganic electrolytes, organic buffering agents, or combinations.
- Claim 3: specific list including:
- NaCl, KCl, CaCl2, MgCl2
- Na2SO4
- sodium citrate / potassium citrate
- sodium phosphate / potassium phosphate
- sodium acetate
- sodium borate
- boric acid/mannitol complexes
- boric acid/sorbitol complexes
- combinations
- Claim 4: narrows to NaCl, Na2SO4, or combinations.
So the claim architecture moves from broad chemical classes to a curated ion set. The breadth is meaningful: citrate/phosphate/acetate/borate complexes can be used, but only if they satisfy the SCE requirement and keep tobramycin-polymer ionic interactions within the viscosity performance band.
What viscosity-related performance constraints exist?
- Claim 5: composition has initial viscosity 25 to 175 cps.
- Claim 6: in vitro/in vivo viscosity ratio is 0.01 to 0.65.
These two dependent limits provide additional “performance tethering” that can be used to distinguish close prior art and to police design-around attempts that keep the polymer and actives but shift rheology response outside the target band.
Is the exemplary composition specified?
- Claim 10: specific quantitative embodiment:
- tobramycin 0.3 w/v %
- xanthan gum 0.6 w/v %
- dexamethasone 0.05 w/v %
- Claim 11: pH about 5.7
Claims 16-19 repeat this same exemplar with additional rheology ratio and ion narrowing.
What do Claims 12 and 13 cover?
Claims 12 and 13 claim a method:
- Claim 12: treating ophthalmic inflammatory conditions where either infection or risk of infection exists, by topically applying a therapeutically effective amount of the composition of Claim 1.
- Claim 13: same treatment framing, but using the composition of Claim 10 (the exemplar concentrations).
This is a common structuring in ophthalmic combination products: the medical use attaches to the formulation rather than to a novel method of therapy. The practical value is in expanding enforceability to infringement through therapeutic topical administration, not only through product manufacture.
What changes in Claims 14-19 (in vitro/in vivo viscosity ratio recast)?
Claim 14 restates the core composition but adds (and makes explicit) a further limitation:
- Adds: in vitro/in vivo viscosity ratio 0.01 to 0.65
Then Claim 15 narrows ions again to:
Claim 16 uses the exemplar actives/concentrations:
- 0.3 w/v % tobramycin
- 0.6 w/v % xanthan gum
- 0.05 w/v % dexamethasone
Claim 17 expands allowed ionizable species back out to the broader list including:
- NaCl, KCl, CaCl2, MgCl2, Na2SO4, sodium citrate, potassium citrate, sodium phosphate, potassium phosphate, sodium acetate, sodium borate, boric acid/mannitol, boric acid/sorbitol, and combinations
Claims 18 and 19 then narrow again:
- Claim 18: ions selected from NaCl and/or Na2SO4
- Claim 19: composition contains the exemplar concentrations.
Net effect: the patent offers multiple “lanes” of infringement coverage.
- If you match the ionic window + viscosity behavior + pH and use deacetylated xanthan gum, you can land in multiple claim pathways.
- If you change the ionizable species selection, Claims 2-4 and 15-18 create branch points that control whether the formulation still falls within specific dependent claim scaffolds.
How tight are the claim boundaries for design-around?
1) The ionic strength anchor is stringent
- Required: SCE ionic concentration 134-150 mM
- Many ophthalmic products use sodium chloride in ranges that can drift with buffer systems, tonicity agents, and pH adjustment. Even if the formulation stays isotonic, it may not meet the SCE window as defined in the claim.
2) Polymer identity and concentration are explicit
- Polymer must be deacetylated xanthan gum
- Concentration must be 0.3 to 0.9% w/v
- A substitution to regular xanthan gum (or partially deacetylated variants not within the same identity definition) is a major potential route for avoiding literal infringement. The enforceability depends on how “deacetylated xanthan gum” is interpreted and whether equivalents are argued.
3) Viscosity is not just “thick”; it is measured under defined conditions
- Must be 10 to 300 cps at:
- shear rate 6 sec−1
- temperature 25°C
- Initial viscosity limited to 25 to 175 cps in Claim 5.
- In vitro/in vivo viscosity ratio limited to 0.01 to 0.65 in Claims 6 and 14-19.
This combination creates multiple checkpoints for infringement: even if a formulation appears within a “typical ophthalmic gel viscosity” range, it can fail if it does not match the specified rheology and viscosity ratio metrics.
4) pH window is narrow
- Required pH 5 to 6, with exemplar about 5.7
- pH affects polymer hydration/charge and can affect both viscosity and interaction with ionic species and drug actives.
5) Ionizable species are controlled but still broad enough to allow formulation flexibility
Claims allow many ionizable systems (electrolytes and buffers), but the required SCE 134-150 mM and rheology constraints effectively “compress” that flexibility.
Practical claim coverage map (what a product must match)
Table 1. Claim 1 requirement set (literal infringement checklist)
| Category |
Limitation |
Range / Selection |
| Tobramycin |
Concentration |
0.1 to 0.5 w/v % |
| Dexamethasone |
Concentration |
0.03 to 0.1 w/v % |
| Polymer |
Identity |
deacetylated xanthan gum |
| Polymer |
Concentration |
0.3 to 0.9% (w/v) |
| Ions |
SCE ionic concentration |
134 to 150 mM |
| Ions |
Function |
limit ionic interactions between tobramycin and polymer to maintain viscosity |
| Viscosity (in vitro) |
Magnitude |
10 to 300 cps |
| Viscosity (in vitro) |
Measurement |
shear rate 6 sec−1; 25°C |
| pH |
Window |
5 to 6 |
Patent landscape: likely competitor threat vectors and whitespace
Because the prompt does not provide publication numbers, assignees, filing dates, or cited references tied to US 7,795,316, an exhaustive mapping of family members, prosecution history, and global counterparts cannot be produced from the record provided. What can be done from the claim text alone is to identify the landscape “pressure points” that other product developers must clear.
Likely “threat vectors” (where infringement risk concentrates)
- Combination antibiotic-steroid ophthalmics using polymeric viscosity agents.
- Gels or suspensions employing xanthan gum derivatives with controlled ionic strength.
- Products that independently target:
- tobramycin + dexamethasone
- ophthalmic pH in the ~5-6 region
- viscosity measured and tuned under defined shear regimes
- sodium chloride-equivalent ionic strength around mid-130s to 150 mM
Most plausible “non-infringement” routes (based on claim architecture)
- Use a different polymer system (or a xanthan gum variant that does not meet “deacetylated xanthan gum” identity).
- Shift pH outside 5-6 while maintaining patient tolerability.
- Shift ionic strength outside 134-150 mM SCE.
- Engineer rheology such that viscosity at 6 sec−1 and 25°C falls outside 10-300 cps or fails initial/in vitro-in vivo viscosity ratio constraints.
- Restrict actives to different concentrations that fail the claimed windows (0.1-0.5% tobramycin or 0.03-0.1% dexamethasone).
Landscape segmentation by claim subsets (how competitors may “pick off” dependent claim niches)
- If a competitor uses NaCl/Na2SO4 as the main ionizable species, it aligns more easily with dependent narrowing (Claims 4 and 15-18).
- If it uses broader buffers like citrate/phosphate/borate, it may fall within dependent claims that list those ions (Claims 3, 17), but it still must satisfy the SCE ionic window and viscosity/pH.
What the claim text implies about enforceability strategy
The patent is designed with:
- One independent composition claim with multiple functional performance parameters tethered to specific measurement conditions.
- Dependent claims that add additional performance constraints (initial viscosity; in vitro/in vivo viscosity ratio).
- Dependent claims that narrow the ionic species and include a concrete exemplar.
That structure supports enforceability in three ways:
- Literal coverage for exact formulations and close variants that preserve all performance boundaries.
- Fallback positions via dependent claims that create multiple “entry points” for different degrees of formulation overlap.
- Method claim coverage that can reach infringement via therapeutic topical administration in the indicated patient population (infection or risk of infection with ophthalmic inflammatory conditions).
Key Takeaways
- US 7,795,316 claims a highly specified ophthalmic formulation defined by tobramycin + dexamethasone, deacetylated xanthan gum, SCE ionic concentration 134-150 mM, pH 5-6, and viscosity performance at 6 sec−1 and 25°C in the 10-300 cps band.
- Dependent claims further narrow by initial viscosity (25-175 cps), in vitro/in vivo viscosity ratio (0.01-0.65), and optional specific ion systems (notably NaCl/Na2SO4 subsets).
- The practical infringement risk for competitors concentrates where formulations preserve both the ionic strength window and the rheology metrics under the specified test conditions.
- The most viable design-around strategies inferred from the claim boundaries are shifting polymer identity, pH, SCE ionic concentration, or rheology outcomes (including the in vitro/in vivo viscosity ratio).
FAQs
1) Does Claim 1 require a specific ionizable species or just a specific ionic concentration?
It requires one or more ionizable species present at an amount sufficient to control ionic interactions, with the additional requirement that the ionizable species has SCE ionic concentration of 134 to 150 mM. Dependent claims then restrict species selection.
2) Are viscosity requirements tied to a standard test?
Yes. Claim 1 requires in vitro viscosity maintained within 10 to 300 cps at shear rate 6 sec−1 and 25°C.
3) Do the claims cover only compositions or also treatments?
Both. Claims 12 and 13 cover treating ophthalmic inflammatory conditions with infection or risk of infection by topical application of the claimed compositions.
4) What is the significance of the “in vitro/in vivo viscosity ratio” limitation?
It is a narrowing performance constraint in Claims 6 and 14-19, setting a specific ratio window of 0.01 to 0.65, which can distinguish close rheology designs that otherwise meet the viscosity band.
5) Is there an explicit “example” formulation in the claims?
Yes. Claim 10 provides an explicit embodiment: tobramycin 0.3 w/v %, xanthan gum 0.6 w/v %, dexamethasone 0.05 w/v %, and Claim 11 specifies pH about 5.7.
References
[1] Provided claim text for US Patent 7,795,316 (claims 1-19) as included in the prompt.
